TALAPRO-2 and First-Line mCRPC Treatment: Insights on OS Benefits and Treatment Sequencing

Alan Tan, MD, Vanderbilt University Medical Center, shares key insights from the TALAPRO-2 trial, discussing the overall survival benefit of talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer.

He explores the synergy between PARP inhibitors and ARSIs, the role of HRR testing in patient selection, and how liquid biopsies may improve treatment personalization. Dr. Tan also examines the impact of this combination on treatment sequencing, toxicity management, and evolving therapeutic strategies, including chemotherapy, PSMA-targeted therapies, and emerging clinical trials.

Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Conference Coverage

Live meeting highlights

Noah Hahn, MDUrothelial Carcinoma | February 24, 2025
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
View More
Daniel Joyce, MDRenal Cell Carcinoma | February 24, 2025
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Karine Tawagi, MDProstate Cancer | February 24, 2025
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Karine Tawagi, MDUrothelial Carcinoma | February 24, 2025
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.

Video Insights

Clinical discussions with experts in the field

Network Websites